Allocord Market Growth Fueled by Chronic Disease Prevalence and Personalized Medicine
Dublin, March 13, 2026 – The global allocord market is experiencing significant growth, driven by advancements in treatment options for severe combined immunodeficiency (SCID) and a broader expansion into therapies for inherited immunodeficiencies and chronic diseases. A new report from ResearchAndMarkets.com highlights the evolving landscape of this sector, emphasizing the increasing role of cord blood banking services in regenerative medicine.
Historical Growth and Current Trends
Historically, limited treatment options for SCID and a reliance on bone marrow transplantation spurred advancements in immune disorder diagnosis and the expansion of hospital transplant programs. Though, the current growth trajectory is being significantly influenced by increasing diagnoses of inherited immunodeficiencies and the proliferation of advanced biologic therapies. Key trends shaping the market include the growing utilization of cellular and enzyme therapies, expanded treatment applications for severe immunodeficiency, and a rising focus on personalized immune therapies. There is similarly increased adoption of allocord treatments for rare genetic disorders and a strengthening of hospital-based specialty care initiatives.
The Impact of Chronic Diseases
The rising prevalence of chronic diseases is a major driver of allocord market growth. These long-term health conditions, often requiring continuous management, are influenced by factors such as lifestyle changes, socioeconomic disparities, aging demographics, and urbanization. Allocord plays a pivotal role by providing cord blood banking services, facilitating access to stem cell-based regenerative therapies. For example, Allergy UK reported that over 21 million individuals in the UK were affected by allergies, a common chronic health condition, and projections suggest that by 2026, half of Europe’s population could experience at least one allergy.1
Healthcare Expenditure and Personalized Medicine
Increased healthcare expenditure is also contributing to market expansion. Factors such as population aging, chronic disease prevalence, rising service costs, and technological advancements are propelling healthcare spending. Allocord, through its cord blood banking services, aligns with this financial uptrend by enabling advanced regenerative therapies, which potentially offer cost-effective treatment solutions. The UK’s Office for National Statistics reported a 5.6% increase in total healthcare expenditure in 2023.
the growing interest in personalized medicine – tailoring treatments based on individual genetic, environmental, and lifestyle factors – is set to fuel the market further. This approach is supported by advancements in genomics and precision diagnostics. The Personalized Medicine Coalition reported the approval of 16 new personalized treatments by the US FDA in 2023, a significant increase from the previous year.
Regional Market Dynamics and Key Players
North America currently leads the allocord market, as of 2025. However, the Asia-Pacific region is poised for rapid growth during the forecast period. SSM Cardinal Glennon Children’s Medical Center is identified as a prominent player in the market.2 Tariffs affecting the costs of imported biological materials and specialized equipment, particularly in regions with limited local capabilities, also influence the market, spurring local processing initiatives and regional collaborations.
Allocord Applications and Scope
The allocord market encompasses a range of therapeutic applications through hematopoietic progenitor cell products, injectable suspension offerings, and cryopreserved units. These applications address gaps in unmet medical needs and continue to drive forward the global healthcare landscape. The report’s scope includes formulations like injectable suspensions and cryopreserved units, clinical indications such as hematopoietic disorders, immunologic disorders, inherited disorders, and acquired disorders. It also covers end users including adult, pediatric, and geriatric patients, and distribution channels such as hospitals, clinics, retail, and specialty pharmacies. The geographic scope includes Australia, India, China, South Korea, Japan, the UK, France, Germany, the USA, Canada, and regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.3,4
Looking Ahead
The allocord market demonstrates extensive scope and dynamic potential, offering a comprehensive overview and a positive future outlook. Continued advancements in regenerative medicine, coupled with increasing awareness and accessibility of cord blood banking, are expected to drive sustained growth in the coming years.
1 ResearchAndMarkets.com – Allocord Market Report 2026
2 Yahoo Finance – Allocord (SSM Cardinal Glennon Children’s Medical Center) Market
3 The Business Research Company – Allocord Global Market Report
4 Healthcare Research Reports – Global Allocord Market 2026-2030
Worth a look